The temporary waiver would apply to certain IP on COVID-19 medical tools and technologies until herd immunity is reached. It was originally proposed by India and South Africa in October 2020, and is now officially backed by 58 sponsoring governments, with around 100 countries supporting the proposal overall.
"Even after one year of this pandemic, and 2.5 million deaths, we still see certain governments denying that removing monopolies on COVID-19 medical tools will help increase people’s access to needed treatments, vaccines and tests going forward,” said Dr Christos Christou, MSF’s international president.
“The waiver proposal offers all governments opportunities to take action for better collaboration in development, production and supply of COVID medical tools without being restricted by private industry’s interests and actions, and crucially would give governments all available tools to ensure global access. Countries must stop stonewalling and show the leadership required to deliver on the ‘global solidarity’ they have so often declared during this pandemic. It’s time to champion access to medical tools for everyone, wherever they live."
UK government must stop blocking
“If the UK government is truly serious about ending this pandemic as fast as possible, they have to rethink their opposition to this proposal," said Roz Scourse, policy advisor at MSF.
"Leaving people in other countries with no access to vaccines or other COVID-19 tools like tests or PPE will not only cause huge suffering but it will end up hurting the UK too. If vaccine-resistant variants take hold while the pandemic continues to spread, they risk undermining the success of the UK’s vaccine programme and leading to yet more suffering, deaths and lockdowns here and in other countries. The waiver is a chance to speed up the world’s response to COVID-19. It would be immoral but also deeply self-defeating for the UK to block this opportunity.”
“The UK government has so far invested £337 million in COVID-19 vaccine research and development. More broadly, the six frontrunner vaccine candidates have received over £7 billion of public funds from the UK and other governments. These products should be global public goods, not held as the private property of pharmaceutical companies during a global pandemic. A recent poll found that three-quarters of the British public believe that the government should prevent companies having monopolies on COVID-19 vaccines,” said Scourse.
As variants spread, tools must be accessible
With highly infectious new variants of the coronavirus spreading in many low- and middle-income countries, it is critical to ensure any existing and upcoming medical tools are accessible in sufficient quantities and in a timely way, especially for frontline health workers in developing countries, including MSF teams.
If increasing the number of global suppliers of medical tools is not prioritized, people in these countries will remain in a disproportionately disadvantageous position for access. The proposed IP waiver could provide a more expedited and automatic policy option for governments at the international level to facilitate increased access instead of only relying on voluntary measures by the pharmaceutical industry.
Enabled by IP monopolies, corporations continue to pursue secretive and limited commercial deals that exclude many low-and middle-income countries even in the midst of the pandemic. The waiver proposal could help by removing legal uncertainties and risks for potential producers and governments to quickly start preparing to scale up production and supply of treatments, vaccines, and other essential medical tools.
Waiving monopolies will level the playing field
In Brazil, where healthcare workers have struggled to provide care during multiple waves of the pandemic so far, MSF witnessed how emerging waves saturated the existing health system resulting in rationing of medical equipment and interventions.
“From the early days in the pandemic when governments were competing to get access to certain diagnostics and protective equipment, it was clear that countries like Brazil and many others would be at the back of the line when it came to accessing scarce medical resources,” said Felipe de Carvalho, MSF’s Access Campaign coordinator in Brazil. “Waiving monopolies will help level the playing field in this pandemic and ensure access for all.”
Despite the clear public health benefits that the monopoly waiver proposal offers, a small group of nations is rigorously hindering the start of formal negotiations at the WTO. At the same time, many of the countries blocking or delaying the proposal, including the Australia, Brazil, Canada, the EU, Japan, Norway, Switzerland, the UK and the US, have also secured the majority of available vaccines, much more than needed to vaccinate their entire populations.
“More and more low- and middle-income countries are getting very serious about making this pandemic monopoly waiver a reality, so it’s time for blocking countries to do the right thing and stop standing in the way,” said Yuanqiong Hu, senior legal and policy advisor at MSF’s Access Campaign. “Governments that oppose the monopoly waiver proposal know that simply asking pharmaceutical corporations to voluntarily do the right thing will not get us anywhere, when these attempts have so far failed to secure global access to COVID-19 medical tools for people who urgently need them. It’s time for change, not charity.”
To date, the waiver proposal has gained wide support by hundreds of civil society organizations across the globe, and has been welcomed by a number of international organizations including the World Health Organization (WHO), the United Nations Programme on HIV/AIDS (UNAIDS), the Drugs for Neglected Diseases Initiative (DNDi), South Centre, Unitaid and Third World Network. Recently, over 115 Members of the European Parliament (MEPs) urged the European Commission and the European Council to drop their opposition to the monopoly waiver proposal.